Free Trial
NASDAQ:CMMB

Chemomab Therapeutics Q1 2025 Earnings Report

Chemomab Therapeutics logo
$1.20 +0.02 (+1.69%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$1.20 0.00 (0.00%)
As of 06/24/2025 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Chemomab Therapeutics EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.20
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Chemomab Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Chemomab Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Chemomab Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 20, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Chemomab Therapeutics Earnings Headlines

When This Happens, You Don’t Wait. You Act.
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Chemomab Hikes on Q1 Figures
See More Chemomab Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Chemomab Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chemomab Therapeutics and other key companies, straight to your email.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

View Chemomab Therapeutics Profile

More Earnings Resources from MarketBeat